Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy
Mené à partir d'échantillons sanguins et d'échantillons tissulaires prélevés sur 39 patients atteints d'un cancer du poumon non à petites cellules (durée médiane de suivi : 98 mois), cet essai multicentrique de phase II évalue l'efficacité, du point de vue de la survie sans progression, de l'afatinib administré par voie orale puis examine l'utilité de l'ADN tumoral circulant pour détecter une mutation EGFR et établir un pronostic
Background : Here we present long-term outcomes of first line afatinib in comorbid patients with suspected or confirmed EGFR mutant NSCLC otherwise considered unsuitable for chemotherapy, and the clinical utility of serial ctDNA monitoring.
Methods : TIMELY (NCT01415011) was a multicentre, single arm, phase II trial conducted in the UK. Patients aged
≥
18 were treated with daily oral afatinib (40 mg) until disease progression or unacceptable toxicity. Blood samples for ctDNA analysis were obtained at baseline and 12-weekly until treatment discontinuation. The primary endpoint was PFS.
Results : Thirty-nine patients were enrolled between March 2013 and August 2015. Median follow-up was 98 months (range 69-101). Median PFS was 7.9 months (95% CI 4.6-10.5). Seven patients (18%) continued afatinib beyond 18 months, 3 beyond 36 months and 2 were still on treatment at last follow-up 101 months post-treatment initiation. Analysis of baseline ctDNA samples identified 8 EGFR mutant cases that were not identified by tissue genotyping and ctDNA clearance was associated with improved PFS and OS.
Conclusion : Afatinib is a viable treatment option for tissue or ctDNA-detected EGFR mutant NSCLC comorbid patients, with a proportion achieving long-term clinical benefit. Plasma ctDNA testing improved EGFR mutant identification and its clearance predicted improved PFS and OS.
British Journal of Cancer , article en libre accès, 2024